Sign In
Buy GBT
$68.49
+0 (+0%)
At Close: Jan 27, 2023
Guerbet ha recibido la aprobación de la EMA de EluciremTM como nombre comercial para Gadopiclenol
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet ha recibido la aprobación de la EMA de EluciremTM como nombre comercial para Gadopiclenol.
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol
06:30am, Monday, 13'th Jun 2022 GlobeNewswire Inc.
Guerbet receives EMA acceptance of EluciremTM as the Brand Name for Gadopiclenol.
GBT Presents Positive New Real-World Evidence Data at EHA2022 Congress Further Supporting Clinical Use of Oxbryta® (voxelotor) in Sickle Cell Disease
07:00am, Friday, 10'th Jun 2022 GlobeNewswire Inc.
Positive results from Phase 1 study of GBT601, including incremental new data, support advancing into planned Phase 2/3 trial by mid-year
7 No-Brainer Biotech Stocks to Add to Your Buy List
09:58am, Thursday, 09'th Jun 2022
With the broader markets grumbling, investors should consider biotech stocks to buy for their permanently relevant profile. The post 7 No-Brainer Biotech Stocks to Add to Your Buy List appeared first
Why Is CRISPR Therapeutics AG (CRSP) Up 45.9% Since Last Earnings Report?
03:30pm, Wednesday, 08'th Jun 2022 Zacks Investment Research
CRISPR Therapeutics AG (CRSP) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Global Blood's (GBT) Candidates for SCD Get Two FDA Tags
03:23pm, Tuesday, 07'th Jun 2022 Zacks Investment Research
The FDA bestows both orphan drug and rare pediatric disease designations to Global Blood's (GBT) inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.
Global Blood's (GBT) Candidates for SCD Get Two FDA Tags
12:48pm, Tuesday, 07'th Jun 2022
The FDA bestows both orphan drug and rare pediatric disease designations to Global Blood's (GBT) inclacumab and GBT021601 (GBT601) for the treatment of sickle cell disease.
The GBT Foundation Opens 2022 ACCEL Grant Program to Provide Up to $500,000 in Support to Sickle Cell Disease Nonprofit Healthcare Organizations and Institutions
02:00pm, Monday, 06'th Jun 2022 GlobeNewswire Inc.
Grant proposals accepted through July 29, 2022 Grant proposals accepted through July 29, 2022
Global Blood (GBT) Down 15.5% Since Last Earnings Report: Can It Rebound?
03:32pm, Friday, 03'rd Jun 2022 Zacks Investment Research
Global Blood (GBT) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
GBT Announces New Employment Inducement Grants
08:05pm, Thursday, 02'nd Jun 2022 GlobeNewswire Inc.
SOUTH SAN FRANCISCO, Calif., June 02, 2022 (GLOBE NEWSWIRE) -- Global Blood Therapeutics, Inc. (GBT) (NASDAQ: GBT) today announced that on June 1, 2022, the compensation committee of GBT’s boar
GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
08:05pm, Wednesday, 01'st Jun 2022 GlobeNewswire Inc.
Conference call and webcast will include data presented at EHA 2022 and business and R&D updates
GBT to Host Investor Conference Call on Friday, June 10 and Participate in Upcoming Investor Conferences
04:05pm, Wednesday, 01'st Jun 2022
Conference call and webcast will include data presented at EHA 2022 and business and R&D updates
Global Blood (GBT) Thrives on Oxbryta, Overdependence a Woe
12:48pm, Thursday, 26'th May 2022
Global Blood's (GBT) Oxbryta is approved for treating sickle cell disease. The recent label expansion nod to Oxbryta is a positive.
Global Blood (GBT) Q1 Loss Narrower Than Expected, Revenues Lag
12:03pm, Thursday, 05'th May 2022
Global Blood Therapeutics (GBT) reports y/y wider loss in Q1. Revenues witness a rise.
Global Blood Therapeutics Inc. (GBT) CEO Ted Love on Q1 2022 Results - Earnings Call Transcript
10:39pm, Wednesday, 04'th May 2022
Global Blood Therapeutics, Inc. (NASDAQ:GBT ) Q1 2022 Earnings Conference Call May 4, 2022 4:30 PM ET Company Participants Steven Immergut – Senior Vice Preside, Head-Corporate Communications and In
